Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide

Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited. To determine if ENF could be active in vitro against HIV-1 non-B subtypes and how the gp41 genetic variability across variants may influence ENF susceptibility. Using PHENOSCRIPT ® Env, a recombinant envelope viru...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical virology Vol. 38; no. 2; pp. 176 - 180
Main Authors Holguín, Africa, Faudon, Jean Louis, Labernardière, Jean-Louis, Soriano, Vincent
Format Journal Article
LanguageEnglish
Published Amsterdam Elsevier B.V 01.02.2007
Elsevier Science
Subjects
Online AccessGet full text
ISSN1386-6532
1873-5967
DOI10.1016/j.jcv.2006.09.002

Cover

Abstract Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited. To determine if ENF could be active in vitro against HIV-1 non-B subtypes and how the gp41 genetic variability across variants may influence ENF susceptibility. Using PHENOSCRIPT ® Env, a recombinant envelope virus assay, ENF susceptibility was investigated in isolates from 19 drug-naive HIV-1-infected individuals harboring non-B subtypes. Using phylogenetic analyses of the gp41 gene, distinct HIV-1 subtypes were recognized: A (2), C (5), D (1), F (2), G (1), J (1), CRF02_AG (6) and CRF06 (1). Susceptibility to ENF and IC 50 values in vitro could be obtained in only 13 (68.4%) specimens, most likely due to the high genetic variability in HR1 and HR2 regions in the remaining cases. A wide range of IC 50 values with a median of 0.013 μg/ml was observed (range, 0.005–0.180 μg/ml). Natural polymorphisms, but not classical ENF resistance associated mutations within HR1 (residues 36–45) were identified in most non-B viruses. This study provides information about the baseline susceptibility to ENF in antiretroviral-naive subjects infected with different HIV-1 non-B subtypes. Susceptibility to ENF seems to be preserved despite high genetic variability in HR1 and HR2 regions.
AbstractList Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited. To determine if ENF could be active in vitro against HIV-1 non-B subtypes and how the gp41 genetic variability across variants may influence ENF susceptibility. Using PHENOSCRIPT ® Env, a recombinant envelope virus assay, ENF susceptibility was investigated in isolates from 19 drug-naive HIV-1-infected individuals harboring non-B subtypes. Using phylogenetic analyses of the gp41 gene, distinct HIV-1 subtypes were recognized: A (2), C (5), D (1), F (2), G (1), J (1), CRF02_AG (6) and CRF06 (1). Susceptibility to ENF and IC 50 values in vitro could be obtained in only 13 (68.4%) specimens, most likely due to the high genetic variability in HR1 and HR2 regions in the remaining cases. A wide range of IC 50 values with a median of 0.013 μg/ml was observed (range, 0.005–0.180 μg/ml). Natural polymorphisms, but not classical ENF resistance associated mutations within HR1 (residues 36–45) were identified in most non-B viruses. This study provides information about the baseline susceptibility to ENF in antiretroviral-naive subjects infected with different HIV-1 non-B subtypes. Susceptibility to ENF seems to be preserved despite high genetic variability in HR1 and HR2 regions.
Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited.BACKGROUNDData on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited.To determine if ENF could be active in vitro against HIV-1 non-B subtypes and how the gp41 genetic variability across variants may influence ENF susceptibility.OBJECTIVETo determine if ENF could be active in vitro against HIV-1 non-B subtypes and how the gp41 genetic variability across variants may influence ENF susceptibility.Using PHENOSCRIPT Env, a recombinant envelope virus assay, ENF susceptibility was investigated in isolates from 19 drug-naive HIV-1-infected individuals harboring non-B subtypes.METHODSUsing PHENOSCRIPT Env, a recombinant envelope virus assay, ENF susceptibility was investigated in isolates from 19 drug-naive HIV-1-infected individuals harboring non-B subtypes.Using phylogenetic analyses of the gp41 gene, distinct HIV-1 subtypes were recognized: A (2), C (5), D (1), F (2), G (1), J (1), CRF02_AG (6) and CRF06 (1). Susceptibility to ENF and IC(50) values in vitro could be obtained in only 13 (68.4%) specimens, most likely due to the high genetic variability in HR1 and HR2 regions in the remaining cases. A wide range of IC(50) values with a median of 0.013 microg/ml was observed (range, 0.005-0.180 microg/ml). Natural polymorphisms, but not classical ENF resistance associated mutations within HR1 (residues 36-45) were identified in most non-B viruses.RESULTSUsing phylogenetic analyses of the gp41 gene, distinct HIV-1 subtypes were recognized: A (2), C (5), D (1), F (2), G (1), J (1), CRF02_AG (6) and CRF06 (1). Susceptibility to ENF and IC(50) values in vitro could be obtained in only 13 (68.4%) specimens, most likely due to the high genetic variability in HR1 and HR2 regions in the remaining cases. A wide range of IC(50) values with a median of 0.013 microg/ml was observed (range, 0.005-0.180 microg/ml). Natural polymorphisms, but not classical ENF resistance associated mutations within HR1 (residues 36-45) were identified in most non-B viruses.This study provides information about the baseline susceptibility to ENF in antiretroviral-naive subjects infected with different HIV-1 non-B subtypes. Susceptibility to ENF seems to be preserved despite high genetic variability in HR1 and HR2 regions.CONCLUSIONThis study provides information about the baseline susceptibility to ENF in antiretroviral-naive subjects infected with different HIV-1 non-B subtypes. Susceptibility to ENF seems to be preserved despite high genetic variability in HR1 and HR2 regions.
Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited. To determine if ENF could be active in vitro against HIV-1 non-B subtypes and how the gp41 genetic variability across variants may influence ENF susceptibility. Using PHENOSCRIPT Env, a recombinant envelope virus assay, ENF susceptibility was investigated in isolates from 19 drug-naive HIV-1-infected individuals harboring non-B subtypes. Using phylogenetic analyses of the gp41 gene, distinct HIV-1 subtypes were recognized: A (2), C (5), D (1), F (2), G (1), J (1), CRF02_AG (6) and CRF06 (1). Susceptibility to ENF and IC(50) values in vitro could be obtained in only 13 (68.4%) specimens, most likely due to the high genetic variability in HR1 and HR2 regions in the remaining cases. A wide range of IC(50) values with a median of 0.013 microg/ml was observed (range, 0.005-0.180 microg/ml). Natural polymorphisms, but not classical ENF resistance associated mutations within HR1 (residues 36-45) were identified in most non-B viruses. This study provides information about the baseline susceptibility to ENF in antiretroviral-naive subjects infected with different HIV-1 non-B subtypes. Susceptibility to ENF seems to be preserved despite high genetic variability in HR1 and HR2 regions.
Abstract Background Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited. Objective To determine if ENF could be active in vitro against HIV-1 non-B subtypes and how the gp41 genetic variability across variants may influence ENF susceptibility. Methods Using PHENOSCRIPT® Env, a recombinant envelope virus assay, ENF susceptibility was investigated in isolates from 19 drug-naive HIV-1-infected individuals harboring non-B subtypes. Results Using phylogenetic analyses of the gp41 gene, distinct HIV-1 subtypes were recognized: A (2), C (5), D (1), F (2), G (1), J (1), CRF02_AG (6) and CRF06 (1). Susceptibility to ENF and IC50 values in vitro could be obtained in only 13 (68.4%) specimens, most likely due to the high genetic variability in HR1 and HR2 regions in the remaining cases. A wide range of IC50 values with a median of 0.013 μg/ml was observed (range, 0.005–0.180 μg/ml). Natural polymorphisms, but not classical ENF resistance associated mutations within HR1 (residues 36–45) were identified in most non-B viruses. Conclusion This study provides information about the baseline susceptibility to ENF in antiretroviral-naive subjects infected with different HIV-1 non-B subtypes. Susceptibility to ENF seems to be preserved despite high genetic variability in HR1 and HR2 regions.
Background: Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited. Objective: To determine if ENF could be active in vitro against HIV-1 non-B subtypes and how the gp41 genetic variability across variants may influence ENF susceptibility. Methods: Using PHENOSCRIPT super(()R) Env, a recombinant envelope virus assay, ENF susceptibility was investigated in isolates from 19 drug-naive HIV-1-infected individuals harboring non-B subtypes. Results: Using phylogenetic analyses of the gp41 gene, distinct HIV-1 subtypes were recognized: A (2), C (5), D (1), F (2), G (1), J (1), CRF02_AG (6) and CRF06 (1). Susceptibility to ENF and IC sub(5) sub(0) values in vitro could be obtained in only 13 (68.4%) specimens, most likely due to the high genetic variability in HR1 and HR2 regions in the remaining cases. A wide range of IC sub(5) sub(0) values with a median of 0.013 mu g/ml was observed (range, 0.005-0.180 mu g/ml). Natural polymorphisms, but not classical ENF resistance associated mutations within HR1 (residues 36-45) were identified in most non-B viruses. Conclusion: This study provides information about the baseline susceptibility to ENF in antiretroviral-naive subjects infected with different HIV-1 non-B subtypes. Susceptibility to ENF seems to be preserved despite high genetic variability in HR1 and HR2 regions.
Author Labernardière, Jean-Louis
Holguín, Africa
Soriano, Vincent
Faudon, Jean Louis
Author_xml – sequence: 1
  givenname: Africa
  surname: Holguín
  fullname: Holguín, Africa
  email: aholguin.hciii@salud.madrid.org
  organization: Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
– sequence: 2
  givenname: Jean Louis
  surname: Faudon
  fullname: Faudon, Jean Louis
  organization: Eurofins Viralliance, Paris, France
– sequence: 3
  givenname: Jean-Louis
  surname: Labernardière
  fullname: Labernardière, Jean-Louis
  organization: Eurofins Viralliance, Paris, France
– sequence: 4
  givenname: Vincent
  surname: Soriano
  fullname: Soriano, Vincent
  organization: Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18474447$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/17196877$$D View this record in MEDLINE/PubMed
BookMark eNqFkk2L1TAUhoOMOB_6A9xIN7prPWnTfCAIOozOwKCLUbchTVJI7U2uSXrh_ntT7lVhwJlNTgjP-x7OeXOOTnzwFqGXGBoMmL6dmknvmhaANiAagPYJOsOcdXUvKDsp947TmvZde4rOU5oAcN8R9gydYoYF5YydoS93S9J2m93gZpf3VRir65sfNa5Kq_pjlZYh77c2VcqbKlodNoPzyudqp6IrNVU5VFd-XHYuZmfsc_R0VHOyL471An3_dPXt8rq-_fr55vLDba17zHLNO9WrTvQt74BbAoOiuiVq5JgRa3DPmDCqoEB1eRKAR8JHrDkxylhjoLtAbw6-2xh-LTZluXFljnlW3oYlScpFC4TxR8EWWtqRfnV8dQSXYWON3Ea3UXEv_6yqAK-PgEpazWNUXrv0j-OEEUJWjh04HUNK0Y5Su6yyCz5H5WaJQa7hyUmW8OQangQhS3hFie8p_5o_oHl30Niy7Z2zUSbtrNfWuBJXlia4B9Xv76n17Lwr4_20e5umsERfYpRYplaCvFs_1PqfgAKUUxQD8X-DR5r_BmH71_0
CitedBy_id crossref_primary_10_1517_14656566_9_13_2349
crossref_primary_10_1517_14656566_2010_522178
crossref_primary_10_3390_v5020595
crossref_primary_10_1089_aid_2009_0151
crossref_primary_10_1089_aid_2008_0134
crossref_primary_10_2217_17469600_2_6_579
crossref_primary_10_2217_17469600_1_3_273
crossref_primary_10_1089_aid_2007_0130
crossref_primary_10_1089_aid_2008_0219
crossref_primary_10_1016_j_jcv_2009_05_001
crossref_primary_10_1057_biosoc_2010_37
crossref_primary_10_1097_QAD_0000000000001796
crossref_primary_10_1089_aid_2009_0014
crossref_primary_10_1586_14787210_2013_844649
crossref_primary_10_1089_aid_2006_0256
crossref_primary_10_3390_v3040347
crossref_primary_10_3390_v4123859
Cites_doi 10.1089/aid.2006.22.357
10.1128/JCM.38.4.1370-1374.2000
10.1089/088922204323087714
10.1128/JCM.28.3.495-503.1990
10.1128/JVI.77.2.1610-1613.2003
10.1128/JVI.79.2.764-770.2005
10.1089/aid.2005.21.430
10.1146/annurev.biochem.70.1.777
10.1097/01.qai.0000174656.71276.d6
10.1089/0889222041725271
10.1097/00002030-200409030-00007
10.1371/journal.pmed.0020112
10.1097/01.aids.0000180785.25800.de
10.1089/aid.2005.21.583
10.1097/01.aids.0000188425.79914.e4
10.1128/JVI.78.14.7582-7589.2004
10.1097/00126334-200306010-00003
10.1128/AAC.49.3.1113-1119.2005
10.1128/JCM.40.11.4313-4316.2002
ContentType Journal Article
Copyright 2006
2007 INIST-CNRS
Copyright_xml – notice: 2006
– notice: 2007 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7U9
H94
7X8
DOI 10.1016/j.jcv.2006.09.002
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
Virology and AIDS Abstracts
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic

MEDLINE

AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1873-5967
EndPage 180
ExternalDocumentID 17196877
18474447
10_1016_j_jcv_2006_09_002
S1386653206003209
1_s2_0_S1386653206003209
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
--M
.1-
.FO
.GJ
.~1
0R~
1B1
1P~
1RT
1~.
1~5
29K
4.4
457
4CK
4G.
53G
5GY
5VS
7-5
71M
8P~
AAAJQ
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AARKO
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABFRF
ABJNI
ABMAC
ABMZM
ABWVN
ABXDB
ACDAQ
ACGFO
ACGFS
ACIEU
ACIUM
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADVLN
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGEKW
AGHFR
AGQPQ
AGUBO
AGYEJ
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CJTIS
CS3
D-I
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
HVGLF
HX~
HZ~
IHE
J1W
KOM
LUGTX
M41
MO0
N9A
O-L
O9-
OAUVE
OD-
OO.
OZT
P-8
P-9
P2P
PC.
Q38
R2-
ROL
RPZ
SCC
SDF
SDG
SDP
SEL
SES
SEW
SPCBC
SSH
SSI
SSZ
T5K
UNMZH
Z5R
~G-
AACTN
AFCTW
AFKWA
AJOXV
AMFUW
RIG
AAIAV
ABLVK
ABYKQ
AJBFU
EFLBG
LCYCR
AAYXX
AGRNS
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7U9
H94
7X8
ID FETCH-LOGICAL-c517t-83a5a39528308e40ba6c24af8174ed15779dac5106c817901f48f1c84dadedd03
IEDL.DBID .~1
ISSN 1386-6532
IngestDate Fri Sep 05 09:26:54 EDT 2025
Fri Sep 05 13:50:45 EDT 2025
Wed Feb 19 01:46:36 EST 2025
Mon Jul 21 09:16:53 EDT 2025
Tue Jul 01 02:51:33 EDT 2025
Thu Apr 24 22:53:06 EDT 2025
Fri Feb 23 02:25:04 EST 2024
Sun Feb 23 10:19:39 EST 2025
Tue Aug 26 19:31:36 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords HIV-1
Subtypes
Enfuvirtide
Drug resistance
Gp41
Microbiology
HIV-1 virus
Retroviridae
Lentivirus
Virology
Virus
Resistance
Sensitivity
Human immunodeficiency virus
Subtype
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c517t-83a5a39528308e40ba6c24af8174ed15779dac5106c817901f48f1c84dadedd03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 17196877
PQID 20263450
PQPubID 23462
PageCount 5
ParticipantIDs proquest_miscellaneous_68920478
proquest_miscellaneous_20263450
pubmed_primary_17196877
pascalfrancis_primary_18474447
crossref_citationtrail_10_1016_j_jcv_2006_09_002
crossref_primary_10_1016_j_jcv_2006_09_002
elsevier_sciencedirect_doi_10_1016_j_jcv_2006_09_002
elsevier_clinicalkeyesjournals_1_s2_0_S1386653206003209
elsevier_clinicalkey_doi_10_1016_j_jcv_2006_09_002
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2007-02-01
PublicationDateYYYYMMDD 2007-02-01
PublicationDate_xml – month: 02
  year: 2007
  text: 2007-02-01
  day: 01
PublicationDecade 2000
PublicationPlace Amsterdam
PublicationPlace_xml – name: Amsterdam
– name: Netherlands
PublicationTitle Journal of clinical virology
PublicationTitleAlternate J Clin Virol
PublicationYear 2007
Publisher Elsevier B.V
Elsevier Science
Publisher_xml – name: Elsevier B.V
– name: Elsevier Science
References Boom, Sol, Salimans, Jansen, Wertheim-van Dillen, van der Noordaa (bib2) 1990; 28
Stanfield-Oakley, Mosier, Davison (bib23) 2005; 10
Mink, Greenberg, Mosier, Janumpalli, Davison, Jin (bib14) 2002; 7
Cilliers, Patient, Pillay, Papathanasopoulos, Morris (bib5) 2004; 20
Fleury, Toni, Lan (bib8) 2006; 22
Poveda, Briz, Soriano (bib18) 2005; 7
Kantor, Katzenstein, Efron (bib12) 2005; 2
Chinnadurai, Munch, Dittmar, Kirchhoff (bib3) 2005; 19
Aghokeng, Ewane, Awazi (bib1) 2005; 21
Rodés, Poveda, Soriano (bib20) 2002; 41
Poveda, Barreiro, Rodes, Soriano (bib17) 2005; 21
Nakemi, Kodama, Ikeuchi (bib15) 2005; 79
Sista, Melby, Davison (bib22) 2004; 18
Xu, Pozniak, Wildfire (bib24) 2005; 49
Labrosse, Labernardiere, Dam (bib13) 2003; 7
Nicastri, Sarmati, d’Éttorre (bib16) 2004; 20
Frater (bib9) 2002; 7
Eckert, Kim (bib6) 2001; 70
Heil, Decker, Sfakianos, Shaw, Hunter, Derdeyn (bib10) 2004; 78
Eshleman, Guay, Wang (bib7) 2005; 40
Rodés, Holguín, Soriano (bib19) 2000; 38
Roman, Gonzalez, Lambert (bib21) 2003; 33
Chinnadurai, Munch, Kirchhoff (bib4) 2005; 19
Holguin, Ramírez de Arellano, Rivas, Soriano (bib11) 2006; 8
Eckert (10.1016/j.jcv.2006.09.002_bib6) 2001; 70
Rodés (10.1016/j.jcv.2006.09.002_bib20) 2002; 41
Nakemi (10.1016/j.jcv.2006.09.002_bib15) 2005; 79
Labrosse (10.1016/j.jcv.2006.09.002_bib13) 2003; 7
Mink (10.1016/j.jcv.2006.09.002_bib14) 2002; 7
Sista (10.1016/j.jcv.2006.09.002_bib22) 2004; 18
Nicastri (10.1016/j.jcv.2006.09.002_bib16) 2004; 20
Frater (10.1016/j.jcv.2006.09.002_bib9) 2002; 7
Poveda (10.1016/j.jcv.2006.09.002_bib17) 2005; 21
Chinnadurai (10.1016/j.jcv.2006.09.002_bib4) 2005; 19
Fleury (10.1016/j.jcv.2006.09.002_bib8) 2006; 22
Rodés (10.1016/j.jcv.2006.09.002_bib19) 2000; 38
Aghokeng (10.1016/j.jcv.2006.09.002_bib1) 2005; 21
Boom (10.1016/j.jcv.2006.09.002_bib2) 1990; 28
Eshleman (10.1016/j.jcv.2006.09.002_bib7) 2005; 40
Xu (10.1016/j.jcv.2006.09.002_bib24) 2005; 49
Chinnadurai (10.1016/j.jcv.2006.09.002_bib3) 2005; 19
Holguin (10.1016/j.jcv.2006.09.002_bib11) 2006; 8
Cilliers (10.1016/j.jcv.2006.09.002_bib5) 2004; 20
Poveda (10.1016/j.jcv.2006.09.002_bib18) 2005; 7
Kantor (10.1016/j.jcv.2006.09.002_bib12) 2005; 2
Roman (10.1016/j.jcv.2006.09.002_bib21) 2003; 33
Stanfield-Oakley (10.1016/j.jcv.2006.09.002_bib23) 2005; 10
Heil (10.1016/j.jcv.2006.09.002_bib10) 2004; 78
References_xml – volume: 7
  start-page: 139
  year: 2005
  end-page: 147
  ident: bib18
  article-title: Enfuvirtide, the first fusion inhibitor to treat HIV infection
  publication-title: AIDS Rev
– volume: 70
  start-page: 777
  year: 2001
  end-page: 810
  ident: bib6
  article-title: Mechanisms of viral membrane fusion and its inhibition
  publication-title: Annu Rev Biochem
– volume: 28
  start-page: 495
  year: 1990
  end-page: 503
  ident: bib2
  article-title: Rapid and simple method for purification of nucleic acids
  publication-title: J Clin Microbiol
– volume: 79
  start-page: 764
  year: 2005
  end-page: 770
  ident: bib15
  article-title: Mutations conferring resistance to HIV-1 fusion inhibitors are restricted by gp41 and rev-responsive element functions
  publication-title: J Virol
– volume: 78
  start-page: 7582
  year: 2004
  end-page: 7589
  ident: bib10
  article-title: Determinants of HIV-1 baseline susceptibility to the fusion inhibitors Enfuvirtide and T-649 reside outside the peptide interaction site
  publication-title: J Virol
– volume: 19
  start-page: 1401
  year: 2005
  end-page: 1405
  ident: bib4
  article-title: Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors
  publication-title: AIDS
– volume: 40
  start-page: 24
  year: 2005
  end-page: 29
  ident: bib7
  article-title: Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012
  publication-title: J Acquir Immune Defic Syndr
– volume: 2
  start-page: 325
  year: 2005
  end-page: 337
  ident: bib12
  article-title: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration
  publication-title: PLoS Med
– volume: 20
  start-page: 477
  year: 2004
  end-page: 482
  ident: bib5
  article-title: Sensitivity of HIV-1 subtype C isolates to entry inhibitor T-20
  publication-title: AIDS Res Human Retroviruses
– volume: 19
  start-page: 1919
  year: 2005
  end-page: 1922
  ident: bib3
  article-title: Inhibition of HIV-1 group M and O isolates by fusion inhibitors
  publication-title: AIDS
– volume: 10
  start-page: S75
  year: 2005
  ident: bib23
  article-title: Impact of mutations in HR2 of HIV-1 env gp41 on susceptibility to Enfuvirtide
  publication-title: Antivir Ther
– volume: 38
  start-page: 1370
  year: 2000
  end-page: 1374
  ident: bib19
  article-title: Emergence of drug resistance mutations in HIV-2 infected subjects undergoing antiretroviral therapy
  publication-title: J Clin Microbiol
– volume: 22
  start-page: 357
  year: 2006
  end-page: 366
  ident: bib8
  article-title: Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data
  publication-title: AIDS Res Hum Retroviruses
– volume: 7
  start-page: 17
  year: 2002
  ident: bib14
  article-title: Impact of HIV-1 gp41 amino acid substitutions (positions 36–45) on susceptibility to T20 (Enfuvirtide)
  publication-title: Antivir Ther
– volume: 33
  start-page: 134
  year: 2003
  end-page: 139
  ident: bib21
  article-title: Uncommon mutations at residue positions critical for Enfuvirtide (T-20) resistance in Enfuvirtide-naive patients infected with B and non-B HIV-1 strains
  publication-title: J Acquir Immune Defic Syndr
– volume: 7
  start-page: 92
  year: 2002
  end-page: 96
  ident: bib9
  article-title: The impact of HIV-1 subtype on the clinical response on HAART
  publication-title: J HIV Ther
– volume: 8
  start-page: 98
  year: 2006
  end-page: 107
  ident: bib11
  article-title: Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes
  publication-title: AIDS Rev
– volume: 20
  start-page: 816
  year: 2004
  end-page: 818
  ident: bib16
  article-title: Non-B HIV-1 subtypes: replicative capacity and responses to antiretroviral therapy
  publication-title: AIDS Res Hum Retroviruses
– volume: 41
  start-page: 4313
  year: 2002
  end-page: 4316
  ident: bib20
  article-title: Rapid assessment of phenotypic resistance to protease inhibitors in HIV group O
  publication-title: J Clin Microbiol
– volume: 18
  start-page: 1787
  year: 2004
  end-page: 1794
  ident: bib22
  article-title: Characterization of determinants of genotypic and phenotypic resistance to Enfuvirtide in baseline and on-treatment HIV-1 isolates
  publication-title: AIDS
– volume: 21
  start-page: 583
  year: 2005
  end-page: 585
  ident: bib17
  article-title: Enfuvirtide is active against HIV-1 group O
  publication-title: AIDS Res Hum Retroviruses
– volume: 7
  start-page: 1610
  year: 2003
  end-page: 1613
  ident: bib13
  article-title: Baseline susceptibility of primary HIV-1 to entry inhibitors
  publication-title: J Virol
– volume: 49
  start-page: 1113
  year: 2005
  end-page: 1119
  ident: bib24
  article-title: Emergence and evolution of Enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41
  publication-title: Antimicrob Agents Chemother
– volume: 21
  start-page: 430
  year: 2005
  end-page: 433
  ident: bib1
  article-title: Enfuvirtide binding domain is highly conserved in non-B HIV-1 strains from Cameroon, West Central Africa
  publication-title: AIDS Res Hum Retroviruses
– volume: 10
  start-page: S75
  year: 2005
  ident: 10.1016/j.jcv.2006.09.002_bib23
  article-title: Impact of mutations in HR2 of HIV-1 env gp41 on susceptibility to Enfuvirtide
  publication-title: Antivir Ther
– volume: 8
  start-page: 98
  year: 2006
  ident: 10.1016/j.jcv.2006.09.002_bib11
  article-title: Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes
  publication-title: AIDS Rev
– volume: 7
  start-page: 139
  year: 2005
  ident: 10.1016/j.jcv.2006.09.002_bib18
  article-title: Enfuvirtide, the first fusion inhibitor to treat HIV infection
  publication-title: AIDS Rev
– volume: 22
  start-page: 357
  year: 2006
  ident: 10.1016/j.jcv.2006.09.002_bib8
  article-title: Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data
  publication-title: AIDS Res Hum Retroviruses
  doi: 10.1089/aid.2006.22.357
– volume: 7
  start-page: 17
  issue: Suppl.
  year: 2002
  ident: 10.1016/j.jcv.2006.09.002_bib14
  article-title: Impact of HIV-1 gp41 amino acid substitutions (positions 36–45) on susceptibility to T20 (Enfuvirtide) in vitro: analysis of primary isolates recovered from patients during chronic Enfuvirtide treatment and site-directed mutants in NL4-3
  publication-title: Antivir Ther
– volume: 38
  start-page: 1370
  year: 2000
  ident: 10.1016/j.jcv.2006.09.002_bib19
  article-title: Emergence of drug resistance mutations in HIV-2 infected subjects undergoing antiretroviral therapy
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.38.4.1370-1374.2000
– volume: 20
  start-page: 477
  year: 2004
  ident: 10.1016/j.jcv.2006.09.002_bib5
  article-title: Sensitivity of HIV-1 subtype C isolates to entry inhibitor T-20
  publication-title: AIDS Res Human Retroviruses
  doi: 10.1089/088922204323087714
– volume: 28
  start-page: 495
  year: 1990
  ident: 10.1016/j.jcv.2006.09.002_bib2
  article-title: Rapid and simple method for purification of nucleic acids
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.28.3.495-503.1990
– volume: 7
  start-page: 1610
  year: 2003
  ident: 10.1016/j.jcv.2006.09.002_bib13
  article-title: Baseline susceptibility of primary HIV-1 to entry inhibitors
  publication-title: J Virol
  doi: 10.1128/JVI.77.2.1610-1613.2003
– volume: 79
  start-page: 764
  year: 2005
  ident: 10.1016/j.jcv.2006.09.002_bib15
  article-title: Mutations conferring resistance to HIV-1 fusion inhibitors are restricted by gp41 and rev-responsive element functions
  publication-title: J Virol
  doi: 10.1128/JVI.79.2.764-770.2005
– volume: 21
  start-page: 430
  year: 2005
  ident: 10.1016/j.jcv.2006.09.002_bib1
  article-title: Enfuvirtide binding domain is highly conserved in non-B HIV-1 strains from Cameroon, West Central Africa
  publication-title: AIDS Res Hum Retroviruses
  doi: 10.1089/aid.2005.21.430
– volume: 70
  start-page: 777
  year: 2001
  ident: 10.1016/j.jcv.2006.09.002_bib6
  article-title: Mechanisms of viral membrane fusion and its inhibition
  publication-title: Annu Rev Biochem
  doi: 10.1146/annurev.biochem.70.1.777
– volume: 40
  start-page: 24
  year: 2005
  ident: 10.1016/j.jcv.2006.09.002_bib7
  article-title: Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012
  publication-title: J Acquir Immune Defic Syndr
  doi: 10.1097/01.qai.0000174656.71276.d6
– volume: 20
  start-page: 816
  year: 2004
  ident: 10.1016/j.jcv.2006.09.002_bib16
  article-title: Non-B HIV-1 subtypes: replicative capacity and responses to antiretroviral therapy
  publication-title: AIDS Res Hum Retroviruses
  doi: 10.1089/0889222041725271
– volume: 7
  start-page: 92
  year: 2002
  ident: 10.1016/j.jcv.2006.09.002_bib9
  article-title: The impact of HIV-1 subtype on the clinical response on HAART
  publication-title: J HIV Ther
– volume: 18
  start-page: 1787
  year: 2004
  ident: 10.1016/j.jcv.2006.09.002_bib22
  article-title: Characterization of determinants of genotypic and phenotypic resistance to Enfuvirtide in baseline and on-treatment HIV-1 isolates
  publication-title: AIDS
  doi: 10.1097/00002030-200409030-00007
– volume: 2
  start-page: 325
  year: 2005
  ident: 10.1016/j.jcv.2006.09.002_bib12
  article-title: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration
  publication-title: PLoS Med
  doi: 10.1371/journal.pmed.0020112
– volume: 19
  start-page: 1401
  year: 2005
  ident: 10.1016/j.jcv.2006.09.002_bib4
  article-title: Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors
  publication-title: AIDS
  doi: 10.1097/01.aids.0000180785.25800.de
– volume: 21
  start-page: 583
  year: 2005
  ident: 10.1016/j.jcv.2006.09.002_bib17
  article-title: Enfuvirtide is active against HIV-1 group O
  publication-title: AIDS Res Hum Retroviruses
  doi: 10.1089/aid.2005.21.583
– volume: 19
  start-page: 1919
  year: 2005
  ident: 10.1016/j.jcv.2006.09.002_bib3
  article-title: Inhibition of HIV-1 group M and O isolates by fusion inhibitors
  publication-title: AIDS
  doi: 10.1097/01.aids.0000188425.79914.e4
– volume: 78
  start-page: 7582
  year: 2004
  ident: 10.1016/j.jcv.2006.09.002_bib10
  article-title: Determinants of HIV-1 baseline susceptibility to the fusion inhibitors Enfuvirtide and T-649 reside outside the peptide interaction site
  publication-title: J Virol
  doi: 10.1128/JVI.78.14.7582-7589.2004
– volume: 33
  start-page: 134
  year: 2003
  ident: 10.1016/j.jcv.2006.09.002_bib21
  article-title: Uncommon mutations at residue positions critical for Enfuvirtide (T-20) resistance in Enfuvirtide-naive patients infected with B and non-B HIV-1 strains
  publication-title: J Acquir Immune Defic Syndr
  doi: 10.1097/00126334-200306010-00003
– volume: 49
  start-page: 1113
  year: 2005
  ident: 10.1016/j.jcv.2006.09.002_bib24
  article-title: Emergence and evolution of Enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.49.3.1113-1119.2005
– volume: 41
  start-page: 4313
  year: 2002
  ident: 10.1016/j.jcv.2006.09.002_bib20
  article-title: Rapid assessment of phenotypic resistance to protease inhibitors in HIV group O
  publication-title: J Clin Microbiol
  doi: 10.1128/JCM.40.11.4313-4316.2002
SSID ssj0015347
Score 1.908425
Snippet Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited. To determine if ENF could be active in vitro against HIV-1 non-B...
Abstract Background Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited. Objective To determine if ENF could be active in...
Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited. To determine if ENF could be active in vitro against HIV-1 non-B...
Background: Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited. Objective: To determine if ENF could be active in vitro...
Data on susceptibility of HIV-1 non-B subtypes to Enfuvirtide (ENF) is rather limited.BACKGROUNDData on susceptibility of HIV-1 non-B subtypes to Enfuvirtide...
SourceID proquest
pubmed
pascalfrancis
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 176
SubjectTerms Adult
Allergy and Immunology
Amino Acid Sequence
Biological and medical sciences
Drug resistance
Enfuvirtide
Female
Fundamental and applied biological sciences. Psychology
Gp41
HIV Envelope Protein gp41 - genetics
HIV Envelope Protein gp41 - immunology
HIV Envelope Protein gp41 - pharmacology
HIV Fusion Inhibitors - pharmacology
HIV Infections - virology
HIV-1
HIV-1 - drug effects
HIV-1 - genetics
HIV-1 - isolation & purification
Human immunodeficiency virus 1
Human viral diseases
Humans
Infectious Disease
Infectious diseases
Male
Medical sciences
Microbiology
Middle Aged
Miscellaneous
Peptide Fragments - pharmacology
Phylogeny
Subtypes
Viral diseases
Virology
Title Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1386653206003209
https://www.clinicalkey.es/playcontent/1-s2.0-S1386653206003209
https://dx.doi.org/10.1016/j.jcv.2006.09.002
https://www.ncbi.nlm.nih.gov/pubmed/17196877
https://www.proquest.com/docview/20263450
https://www.proquest.com/docview/68920478
Volume 38
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhpVAopenTabvVoaeCupIsWfIxDQmblO4lTclNyJYEG9LdpV4v5JLf3pFsbwjNA3LxwYweHs-MRtI3Mwh90eCwOa8pka6uiKhyT2whNJGKllymHPoxdvjntJiciuMzebaF9odYmAir7G1_Z9OTte7fjHtujpez2fiE5TFXW84prNnwjEF8Qqgo69-uNjAPUOhUZCwSk0g93GwmjNd5ve7vI8rNycota9PzpW2AY6ErdXG3L5rWpMOX6EXvTOK9br47aMvPX6GnXXnJy9doetI2CbWSALCXeBHw5Og3YRi2_OQ7btoqHsA22M4djhvjP1WCxeA17J8jPAavFvhgHtr1DAZw_g06PTz4tT8hff0EUkumVkTnVtq8jOlbqPaCVraoubBBwy7EOyaVKp0FUlrUOibqYkHowGotnHXeOZq_RdswIf8e4VBpW0le8xwcsNwzy7hyVDAaQogp1jNEB86Zuk8uHmtcXJgBRXZugNmx6GVhaGmA2Rn6ummy7DJr3EfMh99hhpBRMHIG7P59jdRtjXzTq2ljmGm4oeY_UcqQ2LS8IY0PDTi6ISnX3wU-gADhzNDnQXQMqHG8m7Fzv2gb6IUXuZD0bopClzymUsrQu07mrntXYEa1UruPm_UH9Kw7sI4YnY9oe_W39Z_A01pVo6RKI_Rk7-jHZPoPdG8klw
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKEaISQrxawqP1gROSWT9j5whVqy20e2mLerOc2Ja2gt0V2azUC7-dcR5bVbRF4pJDNGM7k_F4xv48g9AHAw6bD4YS5auSyFIE4nJpiNK04KrNoZ_uDp9M8vG5_HqhLjbQ_nAXJsEqe9vf2fTWWvdvRr00R4vpdHTKRMrVJjiFNRuexQP0UCqhE67v0-81zgNmdFtlLFGTRD4cbbYgr8tq1R9IFOutlVsWpycLV4PIYlfr4m5ntF2UDp-hp703iT93A36ONsLsBXrU1Ze8eokmp03dwlZaBOwVnkc8PvpOGIaYn3zBdVOmHdgau5nHKTL-Wba4GLyCADrhY_Byjg9msVlNoQMfXqHzw4Oz_THpCyiQSjG9JEY45USR8rdQEyQtXV5x6aKBMCR4prQuvANSmlcmZepiUZrIKiO988F7KrbRJgwovEY4lsaVildcgAcmAnOMa08lozHGlGM9Q3SQnK367OKpyMUPO8DILi0IO1W9zC0tLAg7Qx_XLIsutcZ9xHz4HXa4MwpWzoLhv49J38YU6n6e1pbZmltq_9KlDMk15w11_FeHuzc05fq7wAmQUuoM7Q2qY2Eep8MZNwvzpoZWeC6kondT5KbgKZdShnY6nbtuXYMdNVq_-b9R76HH47OTY3t8NPn2Fm11u9cJsPMObS5_NeE9uF3LcredVn8A-QcmKg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Susceptibility+of+HIV-1+non-B+subtypes+and+recombinant+variants+to+Enfuvirtide&rft.jtitle=Journal+of+clinical+virology&rft.au=Holguin%2C+A&rft.au=Faudon%2C+J+L&rft.au=Labernardiere%2C+J+L&rft.au=Soriano%2C+V&rft.date=2007-02-01&rft.issn=1386-6532&rft.volume=38&rft.issue=2&rft.spage=176&rft.epage=180&rft_id=info:doi/10.1016%2Fj.jcv.2006.09.002&rft.externalDBID=NO_FULL_TEXT
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F13866532%2FS1386653207X01008%2Fcov150h.gif